Skip to main content
. 2015 Apr 2;6(17):14953–14969. doi: 10.18632/oncotarget.3621

Figure 2. Combined treatment with GSI-I and BTZ induces apoptosis and decreases the viability of primary T-LPN, but not of normal human T lymphocytes.

Figure 2

A. Microscopic analysis of primary T-LPN cells from patients treated ex vivo with GSI-I (2.5 μM) alone or combined with BTZ (10 nM) for 24 h and stained with Giemsa showed morphological features of apoptosis to be more pronounced after the combination treatment than the single drug treatment. Examples from TLL and MF/SS cases are shown (original magnification: ×400). Combination treatment with GSI-I and BTZ also decreased the viability of primary T-LPN cells collected from patient samples (N = 8) at B. 24 h (*: P < 0.0001 vs. control and GSI-I and †: P < 0.01 vs. BTZ) and C. 48 h (*: P < 0.0001 vs. control, GSI-I, and BTZ). Importantly, the viability of human T lymphocytes was not decreased after the treatment. Data shown represent the means ± SE of 8 different samples.